The Medicines and Healthcare products Regulatory Agency (MHRA) has approved zuranolone (brand name: Zurzuvae) to treat moderate or severe postnatal depression (PND) in adults following childbirth.

Postnatal depression is a type of depression that many parents experience after having a baby. It is a common problem, affecting more than 1 in every 10 women within a year of giving birth.

Common symptoms of PND include persistent feelings of sadness or inadequacy, irritability, anxiety about their baby’s wellbeing, and loss of interest in previously enjoyable activities, accompanied by physical manifestations such as extreme fatigue, disrupted sleep patterns, and changes in appetite.

Zuranolone is the first oral treatment for postnatal depression approved in the UK.

The MHRA conducted a rig

See Full Page